Clinical Development, In-Vitro, In-Vivo and Research

New research highlights potential of combination cancer treatment

Drug Discovery World

OCTOBER 25, 2023

iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumour survival pathways, has published new research data in the peer-reviewed journal Cancer Research, that supports a strategy of combining autotaxin inhibitor IOA-289 with TGF-β pathway inhibitor IOA-359.

Research

Research In-Vivo In-Vitro Clinical Development

Research partners hope to develop novel antibody-drug conjugates

Drug Discovery World

JANUARY 3, 2023

Mersana Therapeutics and a subsidiary of Merck have entered a research collaboration to discover novel Immunosynthen antibody-drug conjugates (ADCs) directed against up to two targets. . The post Research partners hope to develop novel antibody-drug conjugates appeared first on Drug Discovery World (DDW).

Antibody

Antibody Development Research Drugs

Evotec and Variant Bio partner to develop fibrosis treatments

Drug Discovery World

APRIL 24, 2024

Evotec will identify best-in-class small molecules targeting a key fibrotic pathway with strong genetic support identified by Variant Bio and progress the programme towards the selection of a clinical development candidate(s) using its R&D platform.

Development

Development In-Vivo In-Vitro Genome

Conversations from ESMO Targeted Anticancer Therapies Congress 2024

Drug Discovery World

MARCH 26, 2024

DDW’s Megan Thomas caught up with Oliver Rausch, Chief Scientific Officer at Storm Therapeutics, following the ESMO Targeted Anticancer Therapies Congress 2024, a global meeting focusing on promising new anticancer targets and agents, focusing on those in early phase clinical development. MT: What’s next for STORM’s research?

RNA

RNA In-Vivo In-Vitro DNA

BenevolentAI progresses drug for the potential treatment of ALS

Drug Discovery World

JUNE 6, 2023

In preclinical studies conducted by the company, BEN-34712 was neuroprotective in a patient-derived, disease-relevant in vitro motor neuron/iAstrocyte co-culture model, demonstrating significant efficacy in both sporadic and familial subtypes of ALS.

Drugs

Drugs In-Vivo In-Vitro Clinical Development

Immuno-Oncology Summit Europe 2023: Programme highlights

Drug Discovery World

JULY 3, 2023

From June 20-22, 2023, Cambridge Healthtech Institute hosted the seventh annual Immuno-Oncology Summit Europe in London.

Antibody

Antibody In-Vitro Engineer In-Vivo

Standigm and SK Chemicals Repurpose FDA-approved Drug into Rheumatoid Arthritis Candidate and Apply for Patent through their Open Innovation Partnership

The Pharma Data

JANUARY 6, 2021

The research collaboration is aimed at identifying novel lead compounds and repurposing existing drugs for rheumatoid arthritis and nonalcoholic steatohepatitis, leveraging Standigm’s AI-powered drug discovery platforms : Standigm BEST , Standigm Insight , and Standigm ASK. About Standigm. Standigm is an AI-driven drug discovery company.

FDA Approval

FDA Approval Life Science Drugs In-Vivo

Global Roundup: Overland Pharma Launches in China to Provide Access to Breakthrough Therapies

The Pharma Data

DECEMBER 9, 2020

Uniquely positioned in the rapidly evolving local biotech ecosystem in China in addition to an expansive global presence, Overland will strategically partner to jointly develop innovative, novel therapeutics. We look forward to developing and advancing our differentiated pipeline of novel therapeutics in carefully selected disease areas.”.

In-Vivo

In-Vivo In-Vitro Antibody Development

Evusheld long-acting antibody combination approved in the EU for pre-exposure prophylaxis (prevention) of COVID-19 in a broad population

The Pharma Data

MARCH 29, 2022

Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months Evusheld retains neutralising activity against the Omicron BA.2 6,7 This study also showed Evusheld reduced viral burden and limited inflammation in the lungs (in vivo) across all Omicron variants.6.

Antibody

Antibody In-Vivo Vaccination Vaccine

Kronos Bio Announces Publication of Preclinical Study Results for Investigational CDK9 Inhibitor KB-0742 in Cell Chemical Biology

The Pharma Data

OCTOBER 21, 2020

Research s howed KB-0742 i nhibited a ndrogen r eceptor -d ependent a ctivity and r educed t umor g rowth in c astration -r esistant p rostate c ancer. Company is on t rack to s ubmit an IND in the fourth quarter of 2020 and i nitiate a Phase 1 /2 clinical trial for advanced solid tumors in 2021. SAN MATEO, Calif., SAN MATEO, Calif.,

In-Vivo

In-Vivo In-Vitro Bioavailability Clinical Trials

Betta to commercialise C4 Therapeutics’ CFT8919 in greater China

Pharmaceutical Technology

MAY 31, 2023

It is expected to accelerate the development of CFT8919 in important international markets. In vivo and in vitro pre-clinical studies demonstrated that CFT8919 provides wider coverage of on-target resistant mutations and intracranial activity, indicating its potential to be effective against brain metastases.

Bioavailability

Bioavailability In-Vivo In-Vitro Licensing

The evolution of assays for immuno-oncology research

Drug Discovery World

FEBRUARY 15, 2023

The first such research dates back to 1891, when William Coley attempted to inject heat-inactivated bacteria to treat osteosarcoma. This is an exciting field of cancer research which involves harnessing the body’s own immune system to target cancerous cells. This continues to be the standard of care.

Research

Research In-Vitro In-Vivo Development

Informatics helps virtual biotech bring compound to clinical trial

Drug Discovery World

FEBRUARY 22, 2024

Libra Therapeutics is a San Diego-based biotech focused on developing novel disease-modifying therapeutics, which restore the cellular balance that is disrupted in neurodegenerative diseases. Libra is a completely virtual company, based on a “plug and play concept and mode of operation”, Gill explains.

Clinical Trials

Clinical Trials Clinical Trials Trials In-Vivo

Can liquid biopsies transform precision medicine?

Drug Discovery World

JANUARY 17, 2024

Challenges in the Oncology Clinical Trials Space The oncology market is a key growth driver for the pharma industry, with global drug revenues expected to reach US$390 billion by 2027 and the annual number of new cancer cases set to grow from 18 to 27 million by 2040 1,2.

Medicine

Medicine DNA Genome Genomics

Clinical Research Informer

New research highlights potential of combination cancer treatment

Research partners hope to develop novel antibody-drug conjugates

Trending Sources

Evotec and Variant Bio partner to develop fibrosis treatments

Conversations from ESMO Targeted Anticancer Therapies Congress 2024

BenevolentAI progresses drug for the potential treatment of ALS

Immuno-Oncology Summit Europe 2023: Programme highlights

Standigm and SK Chemicals Repurpose FDA-approved Drug into Rheumatoid Arthritis Candidate and Apply for Patent through their Open Innovation Partnership

Global Roundup: Overland Pharma Launches in China to Provide Access to Breakthrough Therapies

Evusheld long-acting antibody combination approved in the EU for pre-exposure prophylaxis (prevention) of COVID-19 in a broad population

Kronos Bio Announces Publication of Preclinical Study Results for Investigational CDK9 Inhibitor KB-0742 in Cell Chemical Biology

Betta to commercialise C4 Therapeutics’ CFT8919 in greater China

The evolution of assays for immuno-oncology research

Informatics helps virtual biotech bring compound to clinical trial

Can liquid biopsies transform precision medicine?

Stay Connected